Takeda Pharmaceutical Company
|Founded||Doshomachi, Osaka, Japan (June 12, 1781)|
|Headquarters||1-1, Doshomachi Yonchome, Chuo-ku, Osaka, Japan|
(Chairman of the Board)
(President & CEO)
|Revenue||11px ¥1,557,267 million (FY 2012)[* 1]|
|11px ¥122,505 million (FY 2012)[* 1]|
|#redirect Template:If affirmed||11px ¥131,244 million (FY 2012)[* 1]|
|Total assets||11px ¥3,955,599 million (FY 2012)[* 1]|
|Total equity||11px ¥2,223,359 million (FY 2012)[* 1]|
Number of employees
Footnotes / references|
Takeda Pharmaceutical Company Ltd (武田薬品工業株式会社 Takeda Yakuhin Kōgyō Kabushiki-gaisha?) is the largest pharmaceutical company in Japan and Asia and a top 15 pharmaceutical company. The company has over 30,000 employees worldwide and achieved 16.2 billion USD in revenue during the 2012 fiscal year. The company is focused on metabolic disorders, gastroenterology, neurology, inflammation, as well as oncology through its independent subsidiary, Millennium: The Takeda Oncology Company. Its headquarters is located in Chuo-ku, Osaka, and it has an office in Nihonbashi, Chuo, Tokyo. In January 2012, Fortune Magazine ranked the Takeda Oncology Company as one of the 100 best companies to work for in the United States.
Takeda Pharmaceuticals was founded on June 12, 1781 and was incorporated on January 29, 1925.
In 1977, Takeda first entered the U.S. pharmaceutical market by developing a joint venture with Abbott Laboratories called TAP Pharmaceuticals. Through TAP Pharmaceuticals, Takeda and Abbott launched the blockbusters Lupron (leuprolide) in 1985 and Prevacid (lansoprazole) in 1995.
One of the firm's mainstay drugs is Actos, a compound in the thiazolidinedione class of drugs used in the treatment of type 2 diabetes. Launched in 1999, Actos has become the best-selling diabetes drug in the world with 4 billion USD in sales during the 2008 fiscal year.
In February 2005, Takeda announced its acquisition of San Diego, California-based Syrrx, a company specializing in high-throughput X-ray crystallography, for 270 million USD.
In March 2008, Takeda and Abbott Laboratories announced plans to conclude their 30-year old joint venture, TAP Pharmaceuticals, that had over 3 billion USD in sales in its final year. The split resulted in Abbott acquiring U.S. rights to Lupron and the drug's support staff. On the other hand, Takeda received rights to Prevacid and TAP's pipeline candidates. The move also increased Takeda's headcount by 3,000 employees.
In April 2008, Takeda announced that it was acquiring Millennium Pharmaceuticals of Cambridge, Massachusetts, a company specializing in cancer drug research, for 8.8 billion USD. The acquisition brought in Velcade, a drug indicated for hematological malignancies, as well as a portfolio of pipeline candidates in the oncology, inflammation, and cardiovascular therapeutic areas. Millennium now operates as an independent subsidiary, "Millennium: The Takeda Oncology Company." 
On April 11, 2012, Takeda Pharmaceutical and URL Pharma announced that Takeda will acquire URL Pharma for 800 million USD. The acquisition is expected to be completed within 60 days.
On 30 September 2014, Takeda announced its intention to expand a collaboration with MacroGenics, valued up to 1.6 billion USD. The collaboration will focus on the co-development of the preclinical autoimmune compound MGD010. MGD010 is a therapy which targets the B-cell surface proteins CD32B and CD79B, and is indicated for lupus and rheumatoid arthritis.
Takeda operates two primary bases in Japan in Osaka and Tokyo. Its United States subsidiary is based in Deerfield, Illinois, and all Global Operations outside of Japan and U.S. are based in Opfikon (Zurich), Switzerland. The company maintains research & development sites in Osaka and Tsukuba, Japan; San Diego and San Francisco, United States; Cambridge, United Kingdom; and Singapore.
The company has manufacturing facilities in Japan, China, Indonesia, Italy, and Ireland. Following the Nycomed acquisition, the Takeda manufacturing sites have been extended with facilities in Argentina, Austria, Belgium, Brazil, Denmark, Estonia, Germany, Mexico, Norway and Poland. Takeda has overseas marketing presences in the U.S., UK, France, Italy, Germany, Austria, Switzerland, Spain, China, Taiwan, Philippines, Thailand, Indonesia, and Singapore. It has recently[when?] announced its first foray into Canada, Portugal, Spain, Mexico, and Ireland.
Some of the key products that Takeda produces on behalf of partners include:
- Actos (pioglitazone) - Type 2 Diabetes
- Amitiza (lubiprostone) - Chronic idiopathic constipation
- Basen (voglibose) - Type 2 Diabetes
- Benet (risedronic acid) - Osteoporosis (Japan)
- Blopress (candesartan) - Hypertension
- Enbrel (etanercept) - Inflammatory diseases (Japan)
- Entyvio (vedolizumab) - Crohn's Disease and Ulcerative colitis
- Dexilant (dexlansoprazole) - Gastroesophageal reflux disease - name changed to Dexilant in U.S.
- Lupron/Leuplin (leuprorelin) - GnRH agonist for prostate cancer and endometriosis
- Prevacid/Takepron (lansoprazole) - Gastroesophageal reflux disease
- Rozerem (ramelteon) - Insomnia
- Uloric (febuxostat) - Gout
- Velcade (bortezomib) - Multiple myeloma and mantle cell lymphoma (Millennium Pharmaceuticals)
- Chris Gallagher (2015-03-15). Muralikumar Anantharaman, ed. "Japan drugmaker Takeda says Christophe Weber to become CEO April 1". Reuters. Retrieved 2015-04-20.
- "Financial Results for Fiscal 2012" (PDF). Takeda Pharmaceutical Company Limited. 2013-05-09. Retrieved 2013-06-13.
- "Takeda Initiates Cardiovascular Outcomes Trial for Alogliptin, An Investigational Treatment for Type 2 Diabetes". Newsblaze.com. 2009-08-28. Retrieved 2010-09-18.
- "FAQ." Takeda Pharmaceutical Company. Retrieved on 2011-02-02. "Q : Where is Takeda located? A : The Head Office is located in Osaka, Japan, and the Tokyo Head Office is located in Tokyo, Japan."
- "Overview." Takeda Pharmaceutical Company. Retrieved on 2011-02-02. "Headquarters Head Office 1-1, Doshomachi 4-chome, Chuo-ku, Osaka 540-8645" and "Tokyo Head Office 12-10, Nihonbashi 2-chome, Chuo-ku, Tokyo 103-8668"
- "TAP Pharmaceutical Products, Inc.: Private Company Information - BusinessWeek". Investing.businessweek.com. 2008-04-30. Retrieved 2010-09-18.
- Decker, Susan (2009-07-06). "Takeda Sues Torrent to Stop Generic Copy of Actos Diabetes Pill". Bloomberg. Retrieved 2010-09-18.
- Somers, Terri (2005-02-08). "Japanese drug giant taking over Syrrx here | The San Diego Union-Tribune". Signonsandiego.com. Retrieved 2010-09-18.
- "Takeda, Amgen in exclusive tie-up for Japanese market". MarketWatch. 2008-02-04. Retrieved 2010-09-18.
- Marrazzo, Amanda (2008-05-15). "Featured Articles From The Chicago Tribune". Archives.chicagotribune.com. Retrieved 2010-09-18.
- "MILLENNIUM: The Takeda Oncology Company | About Millennium | Our History". Mlnm.com. Retrieved 2010-09-18.
- staff (2008-06-15). "Takeda Signs On as Alnylam's Asian Partner for $150M Upfront". Genetic Engineering & Biotechnology News (print) (Mary Ann Liebert, Inc.). p. 14.
- Hirschler, Ben (2012-05-25). "Farmacêutica Takeda comprará Multilab por até R$ 540 mi". Grupo Abril (in Portuguese). Exame. Retrieved 2013-01-27.
- "Takeda, BioMotiv Launch $25M Drug Development Partnership". Genetic Engineering & Biotechnology News (Mary Ann Liebert, Inc.). 2014-09-26. Retrieved 2015-04-23.
- "Takeda, MacroGenics Launch Up to $1.6B Expansion of DART Collaboration". Genetic Engineering & Biotechnology News (Mary Ann Liebert, Inc.). 2014-09-30. Retrieved 2015-04-23.
- "Locations | Worldwide | Takeda Pharmaceutical Company Limited". Takedaism.com. Retrieved 2010-09-18.
- "By Business | Worldwide | Takeda Pharmaceutical Company Limited". Takedaism.com. Retrieved 2010-09-18.
- "Annual Reports | Investor Information | Takeda Pharmaceutical Company Limited". Takeda.com. Retrieved 2010-09-18.
- "Actos cancer link nets Eli Lilly, Takeda $9B fine". CBC News (Canadian Broadcasting Corporation). 2014-04-08. Retrieved 2015-04-23.